Time is Muscle!

Presentation to Calgary FSHD 360 Conference

March 16, 2024

Neil Camarta

FSHD | CANADA FOUNDATION

Curing the #1 Form of Muscular Dystrophy

Strategic Plan for SOLVE FSHD



FSHD | CANADA FOUNDATION

Curing the #1 Form of Muscular Dystrophy

- ❑ **Founded in 2012**
- ❑ **47 Projects to Date**
- ❑ **Big Bets**
  - **=> CRISPRi**
  - **=> Mini-Pigs**
  - **=> CTRN**
  - **=> Bio-Markers**
- ❑ **Now Focusing on Muscle Regeneration**

Muscle Regeneration Shots on Goal

SMA FOUNDATION

MYOLOGICA

ECM Therapeutics

X

Epirium Bio

Sarepta biosciences

GOAL!

INmuneBio
INNATE IMMUNITY

ALKAHEST

HARVARD UNIVERSITY

EXTEND BIOSCIENCES

PLIANT

SAT-3247 improves muscle strength in a mouse model of FSHD

Force after 28 days of SAT-3247 dosing - **FSHD**



Force at 150 Hz - **FSHD**



satellos

* p<0.05,

The Wake-Up Call!



The Wake-Up Call!



PROJECT MERCURY

The Global Initiative to Speed the Delivery of Therapies for FSHD

- ❑ Clinical Trial Readiness
- ❑ Patient Access
- ❑ Sustainability

3 Year Plan – US$14.5 Million

Global Collaboration

Critical Projects

Project 1

Organizing and characterizing 10,000 patients in existing FSHD patient registries in Canada, the US, the UK, Europe and Australia. This work requires development of a common digital dataset that all registries will use to collect the same data, the same way. Doing so ensures clinical trials recruit faster and establishes the means for biopharma companies to conduct long-term follow-up studies post-approval.

Project 2

Developing a widely accepted disease progression model based on evidence and clinical and patient input. This work ensures payers have the evidence they need to assess the potential impact and cost-benefit of new treatments to the patient journey. In the absence of this evidence, promising therapies may never get to patients due to payers denying reimbursement.

Project 3

Create a FSHD Centre for Innovation and Technology to quickly test and evaluate new clinical outcome assessments, digital biomarkers to do all we can to optimize the chances of regulators approving promising therapies in development. Will start with advancing projects in MRI, PET scans and potentially a 2D model for RWS assessments.

US$6.8 Million

Time is Muscle!

Questions?

FSHD | CANADA FOUNDATION

Curing the #1 Form of Muscular Dystrophy